Topline
In patients with advanced heart failure, direct injection of autologous mononuclear cells into damaged heart tissue failed to meet the primary endpoint in a major trial, but still showed encouraging results across multiple hard endpoints, prompting the launch of a follow-up FDA-approved study.
Study Details
Presented at the 2025 American College of…
